Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2003

View Archived Issues

Adefovir dipivoxil in chronic hepatitis B

Beneficial effects described for bortezomib in patients with relapsed, refractory myeloma

Potential new molecularly targeted therapies for diseases related to activated PDGFR-alpha

Reduced toxicity and improved antitumor effects for IL-2 when coadministered with M-40403

MDX-010 combined with tumor vaccines in metastatic melanoma

Nonuterotrophic and nonmammotrophic ERbeta ligands presented by Wyeth

Novel PTP1B inhibitors prepared and tested by JT researchers

Pharmasset patent covers new anti-HIV and anti-HBV agents

Series of potassium channel modulators and their use reported by Wyeth

Pfizer researchers present new antidiarrheal agents in recent patent

New telomerase inhibitors under study at Kyowa Hakko

New antiproliferative agents in Sankyo development pipeline

Cytotoxic macrolactones discovered at GBF assumed to act by inhibiting V-ATPase

JNJ-10258859: a novel PDE5 inhibitor with potential in erectile dysfunction

Erectile responses to DA-8159 in rabbit models

Promising activity reported for Nipent combination therapy in NHL

Parenteral anti-MRSA cephalosporin antibiotic characterized by Takeda

Enrollment completed for phase I/II study of 131I-TM-601 in glioma

Theratechnologies completes patient enrollment in phase II ThGRF study

China approves Sumitomo's antianxiety drug Sediel

Daiichi Radioisotope files for marketing approval of Dopascan Injection in Japan

Ivax initiates phase II trial of talampanel for brain cancer

Schering announces positive phase III results for MS-325

BMS presents second-generation farnesyltransferase inhibitors at AACR meeting

Optimization of CDK-2 inhibitor series as orally active antitumor agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...